Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Guillermo Orti, MD, Karl Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Mark Lowdell, PhD, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 2203.

https://doi.org/10.1182/blood.V112.11.2203.2203

Published: 2008

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Ronjon Chakraverty, MD, Nilusha Manji, BSc, Richard Clark, MD, Charles Crawley, MD, Peter Johnson, MD, Effie Liakopoulou, MD, Judith Marsh, MD, Donald Milligan, MD, Emma Morris, MD, Karl Peggs, MD, Kirsty Thomson, MD, John Snowden, MD, Graham Jackson, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1055.

https://doi.org/10.1182/blood.V110.11.1055.1055

Published: 2007

Journal Articles

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Adrian Bloor, MD, Gordon Cook, MD, Donald Milligan, MD, Anne Parker, MD, Charles Craddock, MD, Lynny Yung, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1661.

https://doi.org/10.1182/blood.V110.11.1661.1661

Published: 2007

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

Nicolaus Kroeger, MD, Brownen Shaw, MD, Simona Iacobelli, PhD, Tatjana Zabelina, MD, Karl Peggs, MD, Avichai Shimoni, MD, Arnon Nagler, MD, Thomas Binder, MD, PhD, Rainer Schwerdtfeger, MD, Michael Kiehl, MD, Herbert G. Sayer, MD, Francis Ayuk, MD, Thomas Eiermann, MD, PhD, David Marks, MD

Blood (2004) 104 (11): 980.

https://doi.org/10.1182/blood.V104.11.980.980

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only